The Price Of Test Kit Has Dropped Sharply, And Exports Have "Relaxed" Overseas Demand Or Volume.

In April 26th, the official website of Hubei provincial centralized procurement service platform announced the results of centralized procurement of the new crown virus related reagents in Hubei province. Compared with the average purchasing price of the whole province at the end of March, the price of the nucleic acid detection kit dropped by 81%, and the antibody (IgM/IgG) kit was lowered by 72%.

After the announcement of the above news, the concept of test reagent stocks fell, in the Guoxin Securities senior researcher Zhang Chao Chao, this is superimposed part of short-term funds to meet high cash, but on the whole, the impact of this price on test reagent plate is short-term. A reagent diagnostic enterprise leader told the twenty-first Century economic report reporter that after the sharp decline of the above prices, enterprises still have profits. In the long run, the volume is good for enterprises.

At the same time, Zhang Lichao believes that the normalization and commercialization mechanism of the new crown virus detection helps to respond to the needs of the current school resumption of classes and the resumption of enterprise safety.

Price drop sharply

In April 23rd, the Hubei provincial health insurance bureau introduced a plan to further promote the new crown pneumonia detection and health management services, and launch the centralized procurement of new coronavirus related reagents. This purchase of a new coronavirus (2019-nCoV) antibody (IgM/IgG) kit and a new coronavirus (2019-nCoV) nucleic acid detection kit were conducted.

Up to now, China has approved a total of 30 new coronavirus related detection kits, including 19 nucleic acid detection kits and 11 antibody detection kits. The Hubei new crown virus detection reagent collection of 19 enterprises to declare the bidding, of which 14 declare nucleic acid test reagent group, 5 declare the antibody test reagent set.

In April 26th, the official website of Hubei medical insurance bureau announced that there were 19 enterprises participating in the above test kit, and 6 enterprises were selected. Among them, 4 are nucleic acid detection kits, including Huada bio, Mike bio, Ming De biology and Daan gene, 2 of them, including the Li Zhu reagent of Zhuhai and Nanjing nuwei Zan.

According to the data released by the above agencies, the lowest price of the selected nucleic acid testing reagent enterprises is Mike biological, the price is 16.78 yuan / person, the highest price is Huada biological, the price is 24.99 yuan / person. In the antibody test reagents, the lowest quoted price is Zhuhai Li Zhu reagent, the price is 12.9 yuan / person, Nanjing Nuo Wei Zan price is 13.885 yuan / person.

Hubei Provincial Health Insurance Bureau official website said that the nucleic acid detection kit selected price and the end of March 2020 the province's average purchase price compared to a decrease of 81%; the antibody (IgM/IgG) detection kit selected price and the end of March 2020, the province's average purchasing price, a decrease of 72%. According to the statistics of nucleic acid detection of the largest 89 thousand persons per day in Hubei Province, the decrease in the purchase price of nucleic acid kits can save 8 million yuan per day.

After the sharp decline in the price of nucleic acid detection reagent collection, in April 27th, the Hubei Medical Insurance Bureau jointly issued a document with the Hubei Provincial Health Protection Commission, and temporarily added the new crown virus nucleic acid detection and antibody (IgM/IgG) testing medical service price item in Hubei Province, and set the ceiling price, the maximum price was 180 yuan / 50 yuan / item respectively.

After the price adjustment, the provisional price of nucleic acid detection in Wuhan was reduced by 80 yuan / time, and the provisional price of antibody detection was reduced by 40 yuan / item.

A reagent diagnostic enterprise leader told the twenty-first Century economic news reporter that the winning bid price was much lower than the market price, which removed some of the prices of agents, and the manufacturers still had profits. "For example, the price of the nucleic acid detection kit for the new crown virus in the market last week is about 210 yuan / person, and some antibody detection kits are priced at 100 yuan / share.

In addition, a number of e-commerce platforms have also launched the "new crown nucleic acid detection" service, such as the price of nucleic acid detection after the subsidy of Juhuasuan billion is 69 yuan, the detection price of Jingdong is 258 yuan, and a lot of products have three testing products, which are 179 yuan, 258 yuan and 59 yuan respectively.

According to the estimates of Wanfu biology, Oriental biology and prospectus, the average production cost of the colloidal gold kit is about 1-2 yuan per unit (direct material, direct labor and manufacturing cost). The average production cost of each kit is about 3-5 yuan.

After the above Hubei collection results were released, the detection reagent concept stocks fell, and it was seen by Zhang Lichao, a senior researcher of Guoxin Securities. This is superimposed part of the short-term funds to meet each other's high cash, but on the whole, the impact of the price reduction on the test reagent plate is short term.

According to Anxin securities, because the average production cost of each reagent is very low, it can still ensure that the manufacturer can guarantee a certain rate of profit, and the improvement of the superposition of testing volume and the increase of the leading share will have a positive impact on the overall profits of the leading manufacturers.

Ming De biological also said that the successful bid is expected to enhance the market share of the company's new coronavirus 2019-nCoV nucleic acid detection kit, and has a positive impact on its future operation.

Demand is still huge.

In fact, the incorporation of new crown virus detection agents into medical insurance will also relieve people's burden. In the context of resumption of labor and rehabilitation, the demand for new crown virus detection reagents is also increasing.

In April 22nd, the central meeting of the leading group meeting of the new crown pneumonia epidemic stressed that many countries are stepping up efforts to expand the scope of detection. In order to achieve full recovery and rehabilitation under normal prevention and control, we must speed up the detection capability and carry out large-scale nucleic acid and antibody detection.

In April 28th, Ali released the national thermal map of the new crown nucleic acid detection service. Data show that covering the whole country, there is an urgent need for new crown nucleic acid detection in the southeast coastal provinces, and demand in Hubei, Sichuan, Shaanxi, Heilongjiang and other provinces is also rising. Among them, the five cities in Beijing, Hangzhou, Shanghai, Guangzhou, Wuhan ranked the number of appointments, and the growth rate of consultation in Chengdu, Zhengzhou, Xi'an, Harbin and other cities accelerated.

In addition to expanding domestic demand for testing, the export market is also expected to increase substantially. In April 25th, the Ministry of Commerce, the General Administration of customs and the State Administration of Market Supervision issued the "notice on Further Strengthening the quality supervision of the export of anti epidemic materials". It shows that since April 26th, the export enterprises that have obtained the new standard coronavirus reagents or medical mouthpieces, which have been certified or registered by foreign countries, must submit written declarations when they declare the declaration, and promise that the products are in conformity with the importing countries (regions). Quality standards and safety requirements, customs inspection by the Ministry of Commerce to obtain foreign standards certification or registration list of production enterprises.

"Compared with the relevant documents in March 31st, the export standard is" relaxed "and does not require export enterprises to provide domestic production registration certificates, so that a large number of enterprises can resume normal exports, which will facilitate the export of relevant reagent enterprises. A diagnostic reagent export company told the twenty-first Century economic news reporter that their backlog of orders had now been able to digest normally, and some sectors of the industry had also come down.

In Guangdong securities, it seems that the domestic expansion of the new crown virus detection, superimposed on the overseas epidemic continues to spread, the new crown detection reagent demand is strong, the fundamentals have not changed. In the two quarter, the relevant companies are expected to continue the beautiful performance in the first quarter, and recommend the testing products to obtain the "double certificate" or "three certificates" of the domestic NMPA approval emergency approval and listing, the US FDAEUA certification authority and the European CE certification.